Ask AI

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Gain in-depth knowledge on bispecific antibodies for the management of relapsed/refractory diffuse large B-cell lymphoma, including guideline-informed treatment and expert-informed recommendations to manage treatment-related side effects, through a ClinicalThought commentary and a downloadable self-study slideset.

Share

Program Content

Events

  • Live Event APPlexus Fall 2025: The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care
    APPlexus Fall 2025: The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Bispecific Antibodies for RR DLBCL
The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 25, 2024

Bispecific Antibodies Data in R/R DLBCL
Current Data for Anti-CD20xCD3 Bispecific Antibodies for Relapsed or Refractory DLBCL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 25, 2024

Activities

FAQs: Bispecific Antibodies for R/R DLBCL
Optimizing Bispecific Antibody Therapy for R/R DLBCL: Answers to Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 18, 2024

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC

Supporters

Supported by an educational grant from Genmab US, Inc.

Genmab US, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner